Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.60
+0.04 (+7.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-1.1M · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$150M
P/E
60.0x
↑EV/EBITDA
17.8x
↑ROE
8.3%
↑Gross Margin
43.6%
↓Debt/Equity
1.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.2%
FCF CAGR
—
FCF margin
-3.4%
FCF / Net income
-0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.4M · net income $1.7M · FCF $-1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.4M | $32.4M | $26.6M | $23.4M | $17.8M |
| Net Income | $1.7M | $1.7M | $-16.0M | $-533041.00 | $447458.00 |
| EBITDA | $9.1M | $9.1M | $-8.8M | $3.4M | $3.4M |
| EPS | 0.01 | 0.01 | -0.08 | — | 0.00 |
| Gross Margin | 43.6% | 43.6% | 49.7% | 54.3% | 45.7% |
| Operating Margin | 6.2% | 6.2% | 11.6% | 31.0% | 19.0% |
| Net Margin | 5.3% | 5.3% | -60.1% | -2.3% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 1.28 | 1.28 | 1.20 | 0.58 | 0.71 |
| Current Ratio | 2.99 | 2.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.1M | $-1.1M | $-1.5M | $4.3M | $892892.00 |
| Returns | |||||
| ROE | 8.3% | 8.3% | -178.9% | -4.6% | 6.5% |
| Valuation | |||||
| P/E | 60.00 | 60.00 | — | — | 47.26 |
| EV/EBITDA | 17.81 | 17.81 | — | 18.95 | 7.17 |
| P/B | 6.99 | 6.99 | 22.01 | 5.82 | 3.05 |
| Growth & Yield | |||||
| Revenue Growth | 21.8% | 21.8% | 14.0% | 31.5% | — |
| EPS Growth | 112.5% | 112.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
74.6%
EPS terminal req.
$0.05
Spread vs growth
37.9%
5Y implied EPS CAGR
45.1%
EPS terminal req.
$0.06
Spread vs growth
67.4%
10Y implied EPS CAGR
26.4%
EPS terminal req.
$0.10
Spread vs growth
86.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → 0.01
Residual
+25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.